I was disappointed that the reporter somehow took something Dr. Zivadinov said and got it twisted around to "not only is the procedure unsafe and costly to many patients, it is impeding necessary research." The NPR report could have been much better done.
I believe Dr. Zivadinov was talking about the usefulness of CCSVI treatments, not safety - Buffalo knows the safety of the procedure. BNAC is partnered with University at Buffalo neurosurgeons and developed the first IRB approved CCSVI Treatment Placebo-Controlled Clinical Trial. In June 2010, ten people with MS who met two or more criteria underwent angioplasty treatments as part of Phase 1 of their Treatment Study. This phase tested the safety of the balloon angioplasty treatment procedure. The team is now enrolling 20 more participants in Phase 2 of the study. This phase is blinded to test the placebo effect and, like the initial ten subjects, these subjects will be evaluated periodically over six months.
BNAC is totally involved in their ongoing research into CCSVI, now for two years, to answer the questions:
Are constricted veins the cause, consequence, or important contributing factors of multiple sclerosis?
Are people with CCSVI more susceptible to developing MS?
Is there is a relationship between blocked veins and MS progression?
If CCSVI is present, is treatment needed?
They are committed to quality research and publication of the results which will document the safety and efficacy. Some of what I included above was borrowed from a letter from Dr. Zivadinov - no where did he say the procedure was unsafe. Does anyone believe Buffalo would be going ahead with phase two of the investigation if there had been adverse results from the safety phase?